Asymmetrical Modulation of the Relationship Between the Western Pacific Pattern and El Niño–Southern Oscillation by the Atlantic Multidecadal Oscillation in the Boreal Winter

Abstract Tropical atmospheric convection generated by the El Niño–Southern Oscillation (ENSO) plays a crucial role in affecting the western Pacific pattern (WP) in the boreal winter by triggering an atmospheric teleconnection. Here we show from analysis of observations and model simulations that the Atlantic Multidecadal Oscillation (AMO) asymmetrically modulates the relationship between ENSO and WP. We find a significant modulatory effect of AMO on the relationship between wintertime El Niño and WP. A robust El Niño−WP relation can be attributed to the negative AMO phase (−AMO), yet a weak relationship during the positive AMO phase (+AMO). In contrast, the relationship between La Niña and WP is independent of AMO modulation. Furthermore, during the −AMO period, stronger El Niño amplitudes lead to stronger atmospheric convection anomalies over the tropical western North Pacific, which excites stronger atmospheric teleconnection and thus has a more significant effect on WP than during the +AMO period

Record-breaking summer rainfall in the Asia–Pacific region attributed to the strongest Asian westerly jet related to aerosol reduction during COVID-19

The Asia–Pacific region suffered record rainfall in summer 2020, which was accompanied by the strongest Asian subtropical westerly jet (ASWJ) of the past four decades. Meanwhile, the COVID-19 pandemic spread rapidly around the world, resulting in an abrupt reduction in emissions in East Asia. Here, we investigate whether the enhanced ASWJ induced by plummeting aerosols contributed to the record-breaking rainfall. The results show that tropospheric warming in Southeast Asia, in particular southern China, due to local aerosol reduction, acted to increase the meridional temperature gradients in the mid–lower troposphere, which supported a strong ASWJ in the upper troposphere via the thermal wind balance. The latter enhanced divergence in the upper troposphere over the Asia–Pacific region, which provided a favorable ascending motion for the record rainfall that took place there. Therefore, against a background of carbon neutrality (i.e. the reduction in aerosols), our results imply more strong summer rainfall in the Asia–Pacific region

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

Suvorexant is a first-in-class orexin receptor antagonist for treating insomnia. There is a general concern that hypnotics may impair next-morning driving ability. The objective of this study was to evaluate next-morning driving performance in older adults after single and repeated doses of suvorexant. Double-blind, randomized, placebo-controlled, 4-period crossover study in 24 healthy volunteers (10 females), aged 65-80 years. Subjects were treated with suvorexant (15 and 30 mg) for eight consecutive nights, zopiclone 7.5 mg nightly on days 1 and 8, and placebo. Driving performance was assessed on days 2 and 9 (9 h after dosing) using a 1-h standardized highway driving test in normal traffic, measuring standard deviation of lateral position (SDLP). Drug-placebo differences in SDLP > 2.4 cm were considered to reflect clinically meaningful driving impairment. Driving performance as measured by SDLP was not impaired following suvorexant. Mean drug-placebo differences in SDLP following suvorexant 15 and 30 mg on day 2 and 9 were 0.6 cm or less. Their 90 % CIs were all below the threshold of 2.4 cm for clinical relevance and included zero, indicating effects were not clinically meaningful or statistically significant. Symmetry analysis showed no significant differences between the number of participants who had SDLP differences > 2.4 cm and those who had SDLP differences There was no clinically meaningful residual effect of suvorexant 15 and 30 mg on next-morning driving (9 h after bedtime dosing) in healthy older adults, as assessed by mean changes in SDLP and by the number of participants on drug versus placebo that exceeded a predetermined threshold for clinically meaningful impairment

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers

Study Objective: To evaluate next-morning driving performance in adults younger than 65 years, after single and repeated doses of suvorexant 20 and 40 mg. Design: Double-blind, placebo-controlled, 4-period crossover study. Setting: Maastricht University, The Netherlands. Participants: 28 healthy volunteers (15 females), aged 23 to 64 years. Interventions: Suvorexant (20 and 40 mg) for 8 consecutive nights; zopiclone 7.5 mg nightly on day 1 and 8; placebo. Measurements: Performance on day 2 and 9 (9 h after dosing) using a one-hour standardized highway driving test in normal traffic, measuring standard deviation of lateral position (SDLP). Drug-placebo changes in SDLP > 2.4 cm were considered to reflect meaningful driving impairment. Results: Mean drug-placebo changes in SDLP following suvorexant 20 and 40 mg were 1.01 and 1.66 cm on day 2, and 0.48 and 1.31 cm on Day 9, respectively. The 90% CIs of these changes were all below 2.4 cm. Symmetry analysis showed that more subjects had SDLP changes > 2.4 cm than < -2.4 cm following suvorexant 20 and 40 mg on day 2, and following suvorexant 40 mg on day 9. Four female subjects requested that a total of 5 driving tests-all following suvorexant-stop prematurely due to self-reported somnolence. Conclusions: As assessed by mean changes in standard deviation of lateral position (SDLP), there was no clinically meaningful residual effect of suvorexant in doses of 20 and 40 mg on next-morning driving (9 h after bedtime dosing) in healthy subjects < 65 years old. There may be some individuals who experience next-day effects, as suggested by individual changes in SDLP and prematurely stopped tests